Influenza A Virus, H3N2 Subtype Infections – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Influenza A Virus, H3N2 Subtype Infections – Pipeline Review, H2 2018’, provides an overview of the Influenza A Virus, H3N2 Subtype Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections

– The report reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Influenza A Virus, H3N2 Subtype Infections therapeutics and enlists all their major and minor projects

– The report assesses Influenza A Virus, H3N2 Subtype Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Adimmune Corp

Aphios Corp

AstraZeneca Plc

AusBio Ltd

BiondVax Pharmaceuticals Ltd

Cadila Healthcare Ltd

Celltrion Inc

ContraFect Corp

Emergent BioSolutions Inc

FluGen Inc

Inovio Pharmaceuticals Inc

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Medicago Inc

NanoViricides Inc

Novavax Inc

OPKO Health Inc

Sanofi

Sanofi Pasteur SA

Sarepta Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Influenza A Virus, H3N2 Subtype Infections Overview

Influenza A Virus, H3N2 Subtype Infections Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Influenza A Virus, H3N2 Subtype Infections Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Influenza A Virus, H3N2 Subtype Infections Companies Involved in Therapeutics Development

AbbVie Inc

Adimmune Corp

Aphios Corp

AstraZeneca Plc

AusBio Ltd

BiondVax Pharmaceuticals Ltd

Cadila Healthcare Ltd

Celltrion Inc

ContraFect Corp

Emergent BioSolutions Inc

FluGen Inc

Inovio Pharmaceuticals Inc

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Medicago Inc

NanoViricides Inc

Novavax Inc

OPKO Health Inc

Sanofi

Sanofi Pasteur SA

Sarepta Therapeutics Inc

Influenza A Virus, H3N2 Subtype Infections Drug Profiles

APP-0205 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APP-309 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aspidasept Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-5075S Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-5080 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

B-1201 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-05 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cetylpyridinium chloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-402 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-404 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTP-27 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gamma-Flu Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H3N2] vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H3N2v] vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain H3N2] vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/ Yamagata + B/ Victoria] (quadrivalent) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent, split virion) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strains A/H1N1 + A/H3N2 + B] vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MD-2009 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-2271 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NBP-607 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-8877 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-025 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSC-61610 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVINF-1 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVINF-2 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides for Influenza Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pertussis [strain BPZE1] vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pimodivir hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PNSIA-28 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PrEP-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

radavirsen Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REDEE FLU Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for RSV and Influenza A Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Neuraminidase for Influenza A Virus Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTH-201 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Influenza A Virus, H3N2 Subtype Infections Dormant Projects

Influenza A Virus, H3N2 Subtype Infections Discontinued Products

Influenza A Virus, H3N2 Subtype Infections Product Development Milestones

Featured News & Press Releases

Feb 21, 2018: AstraZeneca announces renewed recommendation and availability of FLUMIST QUADRIVALENT vaccine in the US

Jan 04, 2018: Emergent BioSolutions Initiates Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A Infection

Jan 12, 2017: Study Published in Vaccine Journal Indicates BiondVax’s Universal Flu Vaccine Candidate May Cover Strains Which Don’t Yet Exist

Jun 23, 2016: AstraZeneca provides update on Flumist Quadrivalent Vaccine in the US for the 2016-17 influenza season

Sep 30, 2015: Four-Strain Influenza Vaccine Available this Flu Season in Public Health Programs

Jan 15, 2013: NanoViricides Update: FluCide Drug Candidates Significantly Superior to Tamiflu in Animal Studies Against H3N2 and H1N1 viruses - Company announces that cGMP Facility Project has Entered Detailed Design Phase

Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100

Oct 09, 2012: NanoViricides's Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by AbbVie Inc, H2 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Adimmune Corp, H2 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Aphios Corp, H2 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by AstraZeneca Plc, H2 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by AusBio Ltd, H2 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by BiondVax Pharmaceuticals Ltd, H2 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Cadila Healthcare Ltd, H2 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Celltrion Inc, H2 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by ContraFect Corp, H2 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Emergent BioSolutions Inc, H2 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by FluGen Inc, H2 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Inovio Pharmaceuticals Inc, H2 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Johnson & Johnson, H2 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Medicago Inc, H2 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by NanoViricides Inc, H2 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Novavax Inc, H2 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by OPKO Health Inc, H2 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Sanofi, H2 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Sanofi Pasteur SA, H2 2018

Influenza A Virus, H3N2 Subtype Infections Pipeline by Sarepta Therapeutics Inc, H2 2018

Influenza A Virus, H3N2 Subtype Infections Dormant Projects, H2 2018

Influenza A Virus, H3N2 Subtype Infections Dormant Projects, H2 2018 (Contd..1), H2 2018

Influenza A Virus, H3N2 Subtype Infections Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports